Nektar shareholders approve authorized share increase to 390M and reverse split authorization

NEKTAR THERAPEUTICS

Proposal 5: authorized common shares increased from 300M to 390M (92.5M for, 55.5M against).
Proposal 6: Board authorized to effect reverse stock split at ratio 1:2 to 1:40 within one year (140M for).
Proposal 2: 2017 Performance Incentive Plan amended to add 6M shares (72.4M for, 28.8M against).
Directors Diana Brainard and R. Scott Greer elected; other directors continue.
Ernst & Young ratified as auditor; say-on-pay advisory resolution passed.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.